Avalo Therapeutics Inc (AVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2018 | 12-2017 | 09-2017 | 06-2017 | 03-2017 | |
| Sales | 4,483 | 2,234 | 25,038 | 158 | 384 |
| Cost of Goods | 864 | N/A | N/A | N/A | N/A |
| Gross Profit | 3,619 | 1,598 | 25,038 | 158 | 384 |
| Operating Expenses | 8,237 | 6,591 | 3,116 | 1,933 | 2,283 |
| Operating Income | -3,755 | -4,357 | 21,921 | -1,775 | -1,899 |
| Interest Expense | 100 | -30 | -29 | 26 | 58 |
| Other Income | -5 | -28 | 0 | 2 | -4 |
| Pre-tax Income | -3,860 | -4,355 | 21,951 | -1,799 | -1,961 |
| Income Tax | 23 | -1,264 | 3,230 | N/A | N/A |
| Net Income Continuous | -3,883 | -3,092 | 18,721 | -1,799 | -1,961 |
| Net Income | $-3,883 | $-3,092 | $18,721 | $-1,799 | $-1,961 |
| EPS Basic Total Ops | -342.99 | 657.41 | 1,486.31 | -400.16 | -543.07 |
| EPS Basic Continuous Ops | -354.40 | 276.50 | 2,502.44 | -387.51 | -548.56 |
| EPS Diluted Total Ops | -342.99 | 657.41 | 1,486.31 | -400.16 | -543.07 |
| EPS Diluted Continuous Ops | -354.40 | 245.55 | 2,499.51 | -387.51 | -548.56 |
| EBITDA(a) | $-2,686 | $-3,811 | $21,927 | $-1,769 | $-1,893 |